ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2245

Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.

Anthony M. Reginato1, Changqi Sun2, Elsaid A. Khaled3, Tannin A. Schmidt4, Olin D. Liang5 and Gregory D Jay6, 1Division of Rheumatology, Rhode Island Hospital, Providence, RI, 2Division of Rheumatology, Rhode Island Hospital, Providence, MA, 3Department of Biomedical and Phramaceutical Science, Chapman University School of Pharmacy, Irvine, CA, 4Biomedical Engineering, University of Connecticut Health Center, Framington, CT, 5Division of Hematology/Oncology, Rhode Island Hospital, Providence, RI, 6Department of Emergency Medicine, Rhode Island Hospital, Providence, RI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: gout, inflammasome activation, Inflammation, interleukins (IL) and macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocytes. PRG4 has a multifaceted homeostatic role in the joint including boundary lubrication, friction lowering of apposed cartilage surfaces and prevention of synovial overgrowth. PRG4 is abundant in the synovial fluid (SF) and its levels are reduced in SF from patients with inflammatory arthropathies. Therapeutically, the recombinant and native form of PRG4 has been shown to exhibit a disease a disease-modifying effect in pre-clinical osteoarthritis (OA) models. We recently showed that rhPRG4 reduces phagocytosis of MSU-crystals, activation of chemokines and cytokines, NLRP3 expression, generation of mature IL-1ß, and NFkB nuclear translocation. The objective of this study was to further evaluate role of Lubricin/PRG4 in NLRP3 inflammasome activation, ASC recruitment and speck formation in MSU-crystal stimulation in THP-1 macrophages and wild-type and Prg4 knock-out macrophages.

Methods: We evaluated the impact of recombinant human PRG4 (rhPRG4) on MSU-induced release, secretion and expression of interleukin-1 beta (IL-1ß), NLRP3 induction, caspase-1 activation by ELISA, immunohistochemistry, and Western-blot analysis in MSU-stimulated THP-1 cell and MSU-stimulated peritoneal macrophages (PEM) and bone marrow derived macrophages (BDMPs) from wildtype and Prg4 knock-out (KO) mice. We also evaluated the role of rhPRG4in the expression of the NLRP3 inflammasome components using qPCR, immunohistochemistry and western-blot analysis. Immunohistochemistry experiments were performed to evaluate if rhPRG4 inhibited ASC speck formation and oligomerization. Colocalization of rhodamine rhPRG4 and NLRP3, ASC was evaluated in MSU-stimulated THP-1 cells.

Results: rhPRG4 inhibited the expression of NALP3, PYCARD, Caspase-1 and IL-18 in MSU-stimulated THP-1 cell using immunohistochemistry, western blot analysis and qPCR in a dose dependent manner. rhPRG4 inhibited the formation of ASC speck, a critical marker of NLRP3 inflammasome assembly, in MSU-stimulated cells. PEM from Prg4 -/- mice showed increased NLRP3 induction, caspase-1 activation and conversion of pro-IL-1ß to mature IL-1ß compared to wild-type mice. Colocalization of rhodamine rhPRG4 in MSU-stimulated THP-1 cells showed colocalization with NLRP3 but not ASC.

Conclusion: Our findings advance our current understanding of the complex anti-inflammatory mechanisms of PRG4in gout. One of the rhPRG4’s anti-inflammatory mechanism may be due to targeting the NALP3 inflammasome assembly.

This work is supported by P20GM104937 (AMR and GDT) and Arthritis Foundation Grant (AMR).


Disclosure: A. M. Reginato, None; C. Sun, None; E. A. Khaled, None; T. A. Schmidt, None; O. D. Liang, None; G. D. Jay, None.

To cite this abstract in AMA style:

Reginato AM, Sun C, Khaled EA, Schmidt TA, Liang OD, Jay GD. Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis. [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/lubricin-proteoglycan-4-prg4-inhibits-nlrp3-inflammasome-assembly-in-monosodium-urate-msu-crystal-induced-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lubricin-proteoglycan-4-prg4-inhibits-nlrp3-inflammasome-assembly-in-monosodium-urate-msu-crystal-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology